Dynacure’s quick transfer

A new €47 million ($54.7 million) round will allow Dynacure S.A.S. to begin clinical testing of its lead program to treat centronuclear myopathy (CNM) less than three years after its inception. The round is also the biggest announced yet by a start-up formed via Kurma Partners S.A.’s company creation model, which the French firm revealed in late 2016.

Andera Partners (formerly Edmond de Rothschild Investment Partners) led the new round, which is Dynacure’s first equity installment beyond its initial €2 million ($2.3 million) in seed funding from Kurma. Also participating were existing investor Bpifrance and new investors Pontifax and IdInvest Partners, as well as Kurma...